Zealand Pharma

Zealand Pharma is a biotechnology company based in Copenhagen, Denmark. The company specializes in the discovery, design, and development of innovative peptide-based medicines. Zealand Pharma's portfolio includes medicines for diseases such as diabetes, obesity, cardiovascular diseases, and gastrointestinal diseases.

History

Zealand Pharma was founded in 1998 with the aim of developing novel peptide-based medicines. The company has since grown to become a leader in its field, with several products on the market and a strong pipeline of investigational drugs.

Research and Development

Zealand Pharma's research and development efforts are focused on the therapeutic areas of metabolic diseases, cardiovascular diseases, and gastrointestinal diseases. The company uses its proprietary platform to design and develop peptide-based medicines.

Products

Zealand Pharma's product portfolio includes Lixisenatide (marketed as Lyxumia®), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, and Suliqua™, a combination of Lixisenatide and insulin glargine for the treatment of type 2 diabetes.

Pipeline

Zealand Pharma has a robust pipeline of investigational drugs in various stages of development. These include potential treatments for short bowel syndrome, congenital hyperinsulinism, and obesity.

Partnerships

Zealand Pharma has established partnerships with several major pharmaceutical companies, including Sanofi, Boehringer Ingelheim, and AbbVie.

See Also

• Biotechnology
• Peptide
• Diabetes
• Obesity
• Cardiovascular diseases
• Gastrointestinal diseases

This article is a stub related to pharmacology. You can help WikiMD by expanding it!